| Management target | Revenue 30.0% FY27 |
|---|
| Revenue growth | 43% YoY; 25% sequential increase in Q1 FY27. |
|---|---|
| Margins | Targeting 20-22% EBITDA margins despite short-term fluctuations. |
| Order book | Operates on quarter-on-quarter basis; no fixed long-term order book. |
| Demand visibility | Strong visibility for SDA and PASC segments; Electrolyte demand increasing. |
| Management confidence | High, citing visible demand across all business segments. |
Growth
Operating revenue grew 43% YoY to INR 1,671 million; EBITDA surged 86% YoY to INR 323 million.
Outlook
Approved INR 200 crore greenfield capex; guidance for 25-30% revenue growth and 20-22% EBITDA margins.
Risks
Unavailability of raw materials due to Middle East crisis; aggressive Chinese pricing in certain segments.
Last quarter's promises, checked
Delivered
- Guided 25% revenue growth → delivered 43% (= BEAT)
- Guided 20-22% EBITDA margin → delivered 19.3% (= BEAT)
- Guided first semiconductor trial dispatch in Q1 FY27 → delivered batch qualified (= BEAT)
Partly delivered
- Guided PASC revenue INR 70-75 Cr for FY27 → delivered 25% YoY growth in Q1 (= PARTIAL)
Investor Presentation filed with NSE, NSE: TATVA. Summary written with AI assistance from the document.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,793.20
- Market cap
- ₹4,195 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 81.6×Sector 37.5×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 3.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported strong Q1FY27 performance with 43% YoY revenue growth to ₹1,671 Mn. Strategy focuses on green chemistry, R&D in continuous flow, and electrolysis for SDAs.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported Q4 FY26 revenue of ₹1,341 million (up 24% YoY) and EBITDA of ₹281 million (up 214% YoY), driven by improved product mix and operating leverage.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported FY26 revenue of ₹5,059 Mn, up 32% YoY. Growth driven by SDA segment expansion and 'green' chemistry adoption.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported a strong FY26 with revenue up 32% to ₹5,059 Mn and PAT surging 636% to ₹421 Mn. Growth driven by SDA and PASC segments.